Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% growthImproves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimateIncreases 2026 expected ending cash balance to $8.1-$8.3 billionHighlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company’s fifth approved product globally
Want to stay updated on the latest mining news?
Stay Informed – Subscribe to latest updates. We promise to send only relevant and valuable emails, just insights you care about!
